((自动化翻译由路透提供，请见免责声明 ))
9月12日 - ** 制药商吉利德 股价上涨近2%，至82.55美元
** 该公司称，其艾滋病注射药物来那卡韦（lenacapavir）可将 (link) 艾滋病感染率降低 96%，在第二次晚期试验中优于每日服用的特鲁瓦达（Truvada）。
** 研究对象包括双性恋男性、变性男性、变性女性以及与出生时即被指定为男性的伴侣发生性关系的非二元性别者。
** 今年 6 月，Co 公司称，一项后期研究显示， (link)，长效药物来那卡韦与 Truvada 相比，能更有效地预防女性感染 HIV。
** 公司将在 2024 年底前开始一系列全球监管申报工作
** 股价今年以来上涨 ~2.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.